CRIS Current Research Information System

RIZZO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.380
NA - Nord America 3.049
EU - Europa 1.930
SA - Sud America 221
AF - Africa 206
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.790
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.003
SG - Singapore 1.301
CN - Cina 1.187
VN - Vietnam 905
IT - Italia 452
HK - Hong Kong 340
SE - Svezia 293
DE - Germania 234
KR - Corea 194
GB - Regno Unito 191
BR - Brasile 158
IN - India 151
CH - Svizzera 127
IE - Irlanda 110
FR - Francia 103
NL - Olanda 101
FI - Finlandia 100
RU - Federazione Russa 84
CI - Costa d'Avorio 67
JP - Giappone 48
ID - Indonesia 46
SC - Seychelles 44
PH - Filippine 31
JO - Giordania 30
TG - Togo 26
TR - Turchia 25
CA - Canada 24
ZA - Sudafrica 24
AR - Argentina 23
AT - Austria 23
BG - Bulgaria 23
TH - Thailandia 20
BD - Bangladesh 18
NG - Nigeria 18
PL - Polonia 16
GR - Grecia 14
IQ - Iraq 14
MX - Messico 14
UA - Ucraina 13
PK - Pakistan 10
BE - Belgio 8
EC - Ecuador 8
ES - Italia 8
LT - Lituania 8
CL - Cile 7
CO - Colombia 7
PS - Palestinian Territory 7
TW - Taiwan 7
VE - Venezuela 7
MY - Malesia 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
IR - Iran 5
MA - Marocco 5
PY - Paraguay 5
IL - Israele 4
KE - Kenya 4
CD - Congo 3
HU - Ungheria 3
KZ - Kazakistan 3
PE - Perù 3
SA - Arabia Saudita 3
TN - Tunisia 3
AU - Australia 2
AZ - Azerbaigian 2
BY - Bielorussia 2
CR - Costa Rica 2
CY - Cipro 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EG - Egitto 2
ET - Etiopia 2
GH - Ghana 2
LB - Libano 2
LV - Lettonia 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BO - Bolivia 1
CG - Congo 1
CZ - Repubblica Ceca 1
EE - Estonia 1
FJ - Figi 1
GE - Georgia 1
HR - Croazia 1
HT - Haiti 1
KG - Kirghizistan 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
ML - Mali 1
NP - Nepal 1
OM - Oman 1
Totale 9.786
Salva come PNG Salva come JPEG
Città #
Singapore 896
Hefei 374
Ashburn 331
Hong Kong 318
San Jose 254
Dallas 245
Chandler 226
Ho Chi Minh City 216
Hanoi 207
Seoul 171
Beijing 152
Santa Clara 137
Bern 124
Southend 122
Boardman 121
Council Bluffs 119
Fairfield 116
Bologna 111
Dublin 110
Princeton 107
Dong Ket 96
Los Angeles 77
Helsinki 71
Abidjan 67
Lauterbourg 65
New York 58
Redondo Beach 45
Houston 44
Redmond 41
Woodbridge 41
Buffalo 39
Seattle 39
Guangzhou 37
Frankfurt am Main 36
Haiphong 35
Milan 35
Bengaluru 34
Tokyo 34
Jakarta 33
Wilmington 33
Amman 30
Boydton 30
Cambridge 29
Lomé 26
Da Nang 25
Florence 24
London 24
Shanghai 24
São Paulo 24
Berlin 23
Chicago 22
Lappeenranta 22
Turin 20
Munich 19
Sofia 19
San Diego 17
Rome 16
Shenzhen 16
Nuremberg 15
Biên Hòa 14
Tongling 14
Abeokuta 13
Amsterdam 13
Medford 13
Vienna 13
Hải Dương 12
Can Tho 11
Castel Maggiore 11
Changsha 11
Istanbul 11
Nanjing 11
Johannesburg 10
Zhengzhou 10
Brooklyn 9
Des Moines 9
Stockholm 9
Tân Tiến 9
Ann Arbor 8
Brussels 8
Cape Town 8
Hyderabad 8
Olalla 8
Orem 8
Phoenix 8
Poplar 8
Warsaw 8
Xi'an 8
Chennai 7
Chongqing 7
Harbin 7
Jinan 7
Quận Bình Thạnh 7
Rio de Janeiro 7
Turku 7
Wuxi 7
Yubileyny 7
Atlanta 6
Denver 6
Madrid 6
Mexico City 6
Totale 6.212
Salva come PNG Salva come JPEG
Nome #
Adjuvant treatment in biliary tract cancer 341
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 301
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 230
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 207
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 204
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 198
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 196
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies 195
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 194
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma 184
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 175
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements 171
Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile 166
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 164
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 160
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 159
Bone targeting agents in patients with metastatic prostate cancer: State of the art 157
Skull Metastasis From Uterine Leiomyosarcoma, a Rare Presentation for a Rare Tumor: A Case Report and Review of the Literature 157
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 157
Hacking pancreatic cancer: Present and future of personalized medicine 157
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster 156
Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma 155
The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST) 152
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? 140
Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis 138
Third-and later-line treatment in advanced or metastatic gastric cancer: A systematic review and meta-analysis 137
Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis 136
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 134
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma 130
Genomics and Immunomics in the Treatment of Urothelial Carcinoma 129
Experimental HER2- targeted therapies for biliary tract cancer 127
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures 125
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors 117
Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions 108
Novel HER2-directed treatments in advanced gastric carcinoma: Another paradigm shift? 108
Metabolomic profiling in renal cell carcinoma patients: News and views 107
Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report 106
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges 106
Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer 103
The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy Among Patients with Urothelial Carcinoma: A Meta-Analysis 101
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials 98
Hypothesis on the possible relevance of the immunogenic cell death in the treatment of gestational trophoblastic neoplasms 97
Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review 95
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents 94
Combination therapy of dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer 89
Recurrent Uterine Smooth-Muscle Tumors of Uncertain Malignant Potential (STUMP): State of The Art 88
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue 86
Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma 83
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 83
Cancer immunotherapy: Current and future perspectives on a therapeutic revolution 81
First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: “And Yet It Moves!” 81
Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis 80
Second-line FOLFOX chemotherapy for advanced biliary tract cancer 76
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer 75
Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives 74
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis 71
BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care 71
Microbiota and prostate cancer 69
TRK inhibition in cholangiocarcinoma: Trying to teach an old dog new tricks 69
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? 68
Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis 68
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis 66
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives 65
Cabozantinib for Treatment of Brain Metastases in Patients with Renal Cell Carcinoma 64
The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): A new Pandora's box? 63
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma 61
Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: A meta-analysis 60
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? 58
Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand? 57
The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: Will immunotherapy solve the problem? 56
Atezolizumab in advanced hepatocellular carcinoma: Good things come to those who wait 56
Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis 55
Novel targeted therapies for advanced cholangiocarcinoma 53
Precision oncology in cholangiocarcinoma: current issues in clinical trial design and access to targeted therapies 53
Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis 52
Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: A meta-analysis 52
Recent advances of immunotherapy for biliary tract cancer 51
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma 51
DNA damage response alterations in gastric cancer: Knocking down a new wall 49
In Regard to “A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)” 48
Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis 45
Systemic adjuvant treatment in hepatocellular carcinoma: Tempted to do something rather than nothing 45
Toward personalized therapy for cholangiocarcinoma: new insights and challenges 43
Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis 42
Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma 41
Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer 41
A brand-new CAR for macrophages: Is it time to fire up the engines of a new era for the treatment of renal cell carcinoma? 40
Regarding “HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer” 37
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: A critical overview of recent evidence 36
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma 36
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials 36
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study 35
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma 35
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study 33
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study 30
Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis 30
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma 28
Advances in Novel Systemic Therapies for Advanced Hepatocellular Carcinoma 27
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study 25
Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis 22
Totale 9.861
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.492
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.492
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021191 0 0 0 0 0 0 0 0 0 51 19 121
2021/2022756 41 11 23 42 39 17 16 50 173 54 183 107
2022/20231.462 97 132 60 106 148 163 63 92 223 66 107 205
2023/2024417 67 71 32 29 25 65 14 22 15 36 20 21
2024/20252.011 85 251 232 141 231 87 147 88 32 112 191 414
2025/20264.917 476 546 715 423 476 241 519 250 908 363 0 0
Totale 10.062